As filed with the Securities and Exchange
Commission on January 20, 2023.
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
__________________________
FORM S-8
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933
__________________________
BIOLINERX LTD.
(Exact Name of Registrant as Specified in its Charter)
__________________________
|
State of Israel
|
Not Applicable
|
|
(State or other jurisdiction of
incorporation or organization)
|
(I.R.S. Employer Identification No.)
|
__________________________
BioLineRx Ltd.
2 HaMa’ayan Street
Modi’in 7177871, Israel
(972) (8) 642-9100
(Address of principal executive offices)
__________________________
BioLineRx Ltd. Amended and Restated 2003 Share Incentive Plan
(Full title of the Plan)
__________________________
BioLineRx USA Inc.
77 Fourth Ave
Waltham, Massachusetts 02451
(617) 859-6409
(Name, Address, including zip code, and telephone number, including area code, of agent for service)
__________________________
Copies of all correspondence to:
|
Barry Levenfeld, Adv.
Adrian Daniels, Adv.
Arnon, Tadmor-Levy
22 Rivlin Street
Jerusalem 9424018, Israel
Tel: (972) (2) 623-9220
|
Gary Emmanuel, Esq.
Greenberg Traurig, P.A.
One Azrieli Center
Round Tower, 30th floor
132 Menachem Begin Rd
Tel Aviv 6701101
Tel: +972 3-636-6000
|
__________________________
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company.
See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.
|
Large accelerated filer
|
☐
|
|
Accelerated filer
|
☐
|
|
Non-accelerated filer
|
☒
|
|
Smaller reporting company
|
☐
|
|
|
|
Emerging growth company |
☐ |
EXPLANATORY NOTE
BioLineRx, Ltd. (the “Company”) previously filed a registration statement on Form S-8 (SEC File No. 333-176419)
with the Securities and Exchange Commission (the “SEC”) in connection with the registration of an aggregate of 1,000,000 Ordinary Shares (equivalent to 66,666 ADSs, based on each ADS representing 15 ordinary shares) to be issued under the Plan. In
September 2012, the Company filed another registration statement on Form S-8 (SEC File No. 333-183976) in connection with the registration of an additional 2,000,000 Ordinary Shares (equivalent to 133,333 ADSs, based on each ADS representing 15
ordinary shares) to be issued under the Plan. In December 2014, the Company filed another registration statement on Form S-8 (SEC File No. 333-201326) in connection with the registration of an additional 1,600,000 Ordinary Shares (equivalent to
106,666 ADSs, based on each ADS representing 15 ordinary shares) to be issued under the Plan. In January 2016, the Company filed another registration statement on
Form S-8 (SEC File No. 333-208865) in connection with the registration of an additional 5,000,000 Ordinary Shares (equivalent to 333,333 ADSs, based on each ADS representing 15 ordinary shares) to be issued under the Plan, as amended by
Post-Effective Amendment No. 1 on Form S-8 filed in March 2017. These previously-filed registration statements are referred to collectively herein as the “Prior Registration Statements.”
In accordance with General Instruction E to Form S-8, the Company is filing this registration statement on Form S-8 solely to register an
additional 106,218,486 Ordinary Shares (equivalent to 7,081,232 ADSs, with each ADS representing 15 ordinary shares) which may be issued under the Plan over and above the number of Ordinary Shares issuable pursuant to the Plan that were registered
under the Prior Registration Statements. Pursuant to General Instruction E to Form S-8, the contents of the Prior Registration Statements are hereby incorporated by reference in their entirety, with the exception of Items 3 and 8 of Part II of such
Prior Registration Statements, each of which is amended and restated in its entirety herein.
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 3. Incorporation of Documents by Reference.
The SEC allows the Company to incorporate by reference our publicly filed reports into this prospectus, which means that information included
in those reports is considered part of this prospectus. Information that we file with the SEC after the date of this prospectus will automatically update and supersede the information contained in this prospectus. We incorporate by reference the
following documents filed with the SEC and any future filings we will make with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended:
| |
•
|
|
| |
|
|
| |
•
|
our Reports of Foreign Issuer on Form 6-K filed on January 18, 2022, January
24, 2022, March 3, 2022, March 16, 2022, May 11, 2022, May 27, 2022, June 16, 2022, June 28, 2022, July 5, 2022, August 16, 2022, September 12, 2022, September 15, 2022, September 19, 2022, September
21, 2022, September 27, 2022, November 3, 2022, November
4, 2022, November 10, 2022, November 15, 2022, December
20, 2022, and January 4, 2023 (in each case, to the extent expressly incorporated by reference into our effective
registration statements filed by us under the Securities Act); and
|
| |
|
|
| |
•
|
the description of our ordinary shares contained in Exhibit 2.2 to our Annual Report on Form 20-F for the year ended December 31, 2020, filed with the SEC on February 23, 2021, and any amendment or
report filed for the purpose of further updating that description. |
All documents filed by us pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act after the date of this prospectus and prior to
the filing of a post-effective amendment that indicates that all securities have been offered and sold or that deregisters all securities remaining unsold shall be deemed to be incorporated by reference in the registration statement and to be a part
hereof from the date of filing of such documents (other than information that is furnished in such documents but deemed by the rules of the SEC not to have been filed). Any statement contained in a document incorporated by reference herein shall be
deemed to be modified or superseded for purposes of this prospectus to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes
such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this prospectus.
We will furnish without charge to you, on written or oral request, a copy of any or all of the above documents, other than exhibits to such
documents which are not specifically incorporated by reference therein. You should direct any requests for documents to:
| |
BioLineRx Ltd.
2 HaMa’ayan Street
Modi’in 7177871, Israel
Attention: Corporate Secretary
Tel.: +972-8-642-9100
e-mail: info@BioLineRx.com
|
Item 8. Exhibits.
|
Exhibit
Number
|
|
Exhibit Description
|
|
Method of Filing
|
| |
|
|
|
|
|
|
|
|
|
Incorporated by reference to Exhibit 4.18 the Registrant’s Annual Report on Form 20-F (filed on March 10, 2016).
|
| |
|
|
|
|
|
|
|
|
|
Filed herewith.
|
| |
|
|
|
|
|
|
|
|
|
Filed herewith.
|
| |
|
|
|
|
|
|
|
|
|
Filed herewith.
|
| |
|
|
|
|
|
|
|
|
|
Filed herewith.
|
| |
|
|
|
|
|
|
|
|
|
Filed herewith.
|
Item 9. Undertakings.
The undersigned registrant hereby undertakes:
(1) to file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement;
(i) to include any prospectus required by Section 10(a)(3) of the Securities Act;
(ii) to reflect in the prospectus any facts or events
arising after the effective date of the Registration statement (or most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement.
Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum
offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the change in volume and price represent no more than a 20 percent change in the maximum aggregate offering price set forth
in the “Calculation of Registration Fee” table in the effective Registration Statement; and
(iii) to include any material information with respect to
the plan of distribution not previously disclosed in this Registration Statement or any material change to such information in this Registration Statement; provided, however, that paragraphs (a)(1)(i) and
(a)(1)(ii) of this section do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the SEC by the registrant pursuant to Section 13 or Section
15(d) of the Exchange Act that are incorporated by reference in the Registration Statement;
(2) that, for the purpose of determining any liability
under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
(3) to remove from registration by means of a
post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.
The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the
registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference
in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered herein, and the offering of such securities at that time shall be deemed to be the initial bona
fide offering thereof.
Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons
of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In
the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or
proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a
court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that
it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Modi’in, State of Israel, on January 20, 2023.
.
| |
BIOLINERX LTD.
|
|
| |
|
|
|
| |
By:
|
/s/ Phil Serlin
|
|
| |
|
Phil Serlin
|
|
| |
|
Chief Executive Officer
|
|
KNOW ALL MEN BY THESE PRESENTS, that each director and officer of BIOLINERX LTD. whose signature appears below hereby constitutes and
appoints Phil Serlin and Mali Ze’evi, and each of them severally, acting alone and without the other, his/her true and lawful attorney-in-fact with full power of substitution or re-substitution, for such person and in such person’s name, place and
stead, in any and all capacities, to sign on such person’s behalf, individually and in each capacity stated below, any and all amendments, including post-effective amendments to this Registration Statement, and to sign any and all additional
registration statements relating to the same offering of securities of the Registration Statement that are filed pursuant to Rule 462(b) of the Securities Act of 1933 and to file the same, with all exhibits thereto, and other documents in connection
therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact, full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises, as fully to all intents
and purposes as such person might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact, or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed below by the following persons in the
capacities and on the dates indicated:
|
Name
|
|
Title
|
|
Date
|
| |
|
|
|
|
|
/s/ Philip A. Serlin
|
|
Chief Executive Officer
|
|
January 20, 2023
|
|
Philip A. Serlin
|
|
(principal executive officer)
|
|
|
|
/s/ Mali Ze’evi
|
|
Chief Financial Officer
|
|
|
|
Mali Ze’evi
|
|
(principal financial officer and principal accounting officer)
|
|
|
|
/s/ Aharon Schwartz
|
|
Chairman of the Board
|
|
|
|
Aharon Schwartz, Ph.D.
|
|
|
|
|
| |
|
|
|
|
|
/s/ Michael J. Anghel
|
|
Director
|
|
|
|
Michael J. Anghel, Ph.D.
|
|
|
|
|
|
/s/ Rami Dar
|
|
Director
|
|
|
|
Rami Dar
|
|
|
|
|
| |
|
|
|
|
|
/s/ B.J. Bormann
|
|
Director
|
|
|
|
B.J. Bormann, Ph.D.
|
|
|
|
|
|
/s/ Raphael Hofstein
|
|
Director
|
|
|
|
Raphael Hofstein, Ph.D.
|
|
|
|
|
|
/s/ Avraham Molcho
|
|
Director
|
|
|
|
Avraham Molcho, M.D.
|
|
|
|
|
| |
|
|
|
|
|
/s/ Sandra Panem
|
|
Director
|
|
|
|
Sandra Panem, Ph.D.
|
|
|
|
|
AUTHORIZED REPRESENTATIVE
Pursuant to the Securities Act of 1933, the undersigned, the duly authorized representative in the United States of BioLineRx Ltd. has signed this
registration statement on January 20, 2023.
|
|
BioLineRx USA Inc.
|
|
|
|
|
|
|
By:
|
/s/ Phil Serlin
|
|
|
|
Name: Phil Serlin
|
|
|
|
Title: Authorized Person
|